A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike6-프롤린 안정화된 융합전 스파이크를 발현하는 매우 효과적인 약독화성 볼거리 바이러스 기반 SARS-CoV-2 백신 후보Article Published on 2022-08-162022-09-11 Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibody backbone candidate children COVID-19 vaccine Delta delta variant Delta variants effective expressed expressing expression Genome hamster human vaccine IFNAR1 immune responses Immunity immunization immunogenic Immunoglobulin immunoglobulin A include Infant Infants intranasal junction mice MMR MMR vaccine mucosal mump mumps virus neutralized Neutralizing antibodies neutralizing antibody prefusion proline prolines raised rapid increase Safe SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 USA-WA1/2020 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants sera Spike protein T cell tetravalent Vaccine vaccine strain vaccine. variants virus [DOI] 10.1073/pnas.2201616119 PMC 바로가기 [Article Type] Article
Inactivated vaccine Covaxin/BBV152: A systematic review비활성화 백신 Covaxin/BBV152: 체계적인 검토Article Published on 2022-08-092022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, [키워드] adjusted Administered adverse event Aluminium aluminium hydroxide Antigen AZD1222 BBV152 Beta Bharat binding antibody clinical trial Combination Corona Covaxin Coverage Covishield Delta Delta variants doses Effectiveness Efficacy Evidence evidence of fatality gel heterologous prime-boost hydroxide immunogenicity inactivated Inactivated vaccine India infected individual Local Neutralizing omicron Omicron variant pandemic phase Phase I Phase III trials provided Quinolin reported safety profile Safety. SARS-CoV-2 pandemic screened searched second dose Serious Adverse Event Serious Adverse Events severe COVID-19 surpassed symptomatic infection systematic review systemic adverse events T cell T cell response T cell responses the SARS-CoV-2 Trial vaccination Vaccine Vaccines variant variants virus Zeneca [DOI] 10.3389/fimmu.2022.863162 PMC 바로가기 [Article Type] Article
Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings다양한 임상 환경에서 면역 저하 환자의 오미크론 변이체에 대한 동형 및 이형 면역 반응Article Published on 2022-08-042022-09-11 Journal: Nature Communications [Category] SARS, 변종, 유전자 메커니즘, 진단, 치료기술, 치료법, [키워드] CD4 CD8 Cellular immune response clinical setting comparable controls cross-neutralization D614G Delta Delta variants disease severity dose Host humoral identify immune immune response immune responses Immunocompromised Immunocompromised patient Immunocompromised patients implication Infection magnitude neutralization neutralizing antibody omicron Organ transplant Patient patients peptide peptide pools Pseudovirus neutralization assay Re-infection recipient response responses risk of infection SARS-CoV-2 severe COVID-19 subset T-cell Response T-cell responses uninfected Vaccine variant variants [DOI] 10.1038/s41467-022-32235-x PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trialCOVID-19 회복기 참가자에 대한 FINLAY-FR-1A 백신의 안전성 및 면역원성: 공개 라벨 2a상 및 이중 맹검, 무작위 배정, 위약 대조, 2b상, 심리스, 임상 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adverse event All participants Alpha anti-RBD antibody assigned Asymptomatic Beta clinical clinical trial clinical trials Complete control group control groups convalescent convalescent individual convalescent individuals COVID-19 criteria Cuba defined delta variant Delta variants dimeric double-blind education elicited ELISA Endpoint enrolled Environment evaluate evaluated experimental group first stage geometric mean geometric mean titre geometric mean titres greater hematology ICTRP IgG antibodies immune response immunogenicity immunology increase in injected injection injection site Intervention intervention group Mild minor Moderate COVID-19 natural immunity Negative PCR neutralisation test neutralising antibody Occurrence Open-label Pain participant Participants PCR test per-protocol population Phase 1 Phase 2 Placebo placebo group placebo-controlled prevaccination Primary outcome Primary outcomes Public randomised Randomly Receptor binding domain recruited Registered registry reported Safety safety analysis safety population safety profile SARS-CoV-2 Science seamless secondary Secondary endpoints Serious Adverse Event Serious Adverse Events seroconversion rate sexual single dose stages study population technology the placebo group titre Trial two groups vaccination Vaccine vaccine immunogenicity Virus neutralisation Volunteer was done WHO-ICTRP [DOI] 10.1016/S2213-2600(22)00100-X PMC 바로가기 [Article Type] Clinical Trial
The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach새로운 SARS-CoV-2 변이체 Omicron(B.1.1.529)이 백신 효능에 미치는 영향, Delta 변이체와의 상관관계: 전산적 접근Article Published on 2022-08-012022-09-11 Journal: Microbial pathogenesis [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] addition Analysis antibody approach AY.1 B.1.1.529 binding affinity caused computational analysis correlation COVID CR3022 Delta Delta variants docking docking analysis domain Effect Efficacy Host hosts human ACE2 receptor human monoclonal antibodies Human monoclonal antibody immune evasion in silico Approach In-silico analysis Interaction lead MD simulation Modification Mutation neutralizing antibody new SARS-CoV-2 omicron Omicron variant Omicron. pathogenicity promote Proteins RBD RBD variant Reinfection SARS-CoV-2 variant Spike proteins Strains Structure the binding affinity the WHO Vaccine variant [DOI] 10.1016/j.micpath.2022.105619 PMC 바로가기 [Article Type] Article
Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods철저한 구조 기반 가상 스크리닝, 분자 역학 시뮬레이션을 사용하여 B.1.617.2(델타), AY.1(델타 플러스) 및 C.37(람다) SARS-CoV-2 변이체에서 중요한 스파이크 돌연변이를 타겟팅하기 위한 전산 용도 변경 접근 방식 및 MM-PBSA 방법Article Published on 2022-08-012022-09-11 Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 변종, 신약개발, [키워드] ACE-2 acute respiratory syndrome acute respiratory syndrome coronavirus angiotensin angiotensin-converting enzyme 2 approach Area atovaquone AY.1 B.1.617.2 binding affinity binding site candidate causative agent complex complexes Complexes Compound contagious contribute coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critical Delta delta variant Delta variants docking result docking results drug Drug repurposing drug-likeness drugs eight enzyme FDA approved drug FDA approved Drugs followed by genomic help heparin highest binding affinity Host hydrogen Hydrogen bond identify in silico inhibiting inhibitor inhibitors interact Interaction interactions Lambda Ligand MD simulation MD simulations molecular molecular docking molecular dynamics Molecular dynamics simulation Molecular mechanics morbidity and mortality mortality rates Mutation mutations Praziquantel Protein Proteins RBD Receptor-binding domain reported Research researcher residue SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 variant selected severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Simulation spike spike mutation Spike protein stability surface surface area targets the receptor-binding domain the spike protein variant variants variants of concern viral cell Virtual screening virtual screening. VoC was done was performed wild type Wuhan Wuhan, China [DOI] 10.1016/j.compbiomed.2022.105709 PMC 바로가기 [Article Type] Article
Serial Intervals for SARS-CoV-2 Omicron and Delta Variants, Belgium, November 19-December 31, 2021SARS-CoV-2 Omicron 및 Delta 변종에 대한 일련 간격, 벨기에, 2021년 11월 19일-12월 31일Article Published on 2022-08-012022-09-11 Journal: Emerging Infectious Diseases [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Belgium cause causes coronavirus coronavirus disease COVID-19 Delta delta variant Delta variants faster interval investigated omicron respiratory infections Result SARS-CoV-2 Serial interval severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Transmission vaccination Vaccination Status vaccine-preventable diseases variant variants variants of concern viruses zoonoses zoonoses. [DOI] 10.3201/eid2808.220220 PMC 바로가기 [Article Type] Article
Molecular and computational analysis of spike protein of newly emerged omicron variant in comparison to the delta variant of SARS-CoV-2 in Iraq이라크에서 SARS-CoV-2의 델타 변이체와 비교하여 새로 출현한 오미크론 변이체의 스파이크 단백질의 분자 및 컴퓨터 분석Article Published on 2022-08-012022-09-11 Journal: Molecular biology reports [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 acute respiratory syndrome coronavirus Affect amino acids angiotensin angiotensin converting enzyme binding affinity bioinformatics computational analysis computational tool computational tools concerning contagious contributing to COVID-19 Delta delta variant Delta variants disorder Docking studies docking study engage enzyme greater Health higher affinity human ACE2 human angiotensin converting enzyme 2 hydrophobic amino acid identify Interaction Iraq less molecular molecular docking omicron Omicron variant Omicron variants pathogenicity PCR Phylogenetic analysis physical physical and chemical properties predicted qPCR RBD RBD region Receptor binding domain respiratory SARS-CoV-2 SARS-CoV-2 variants SARS-CoV-2. Sequencing severe acute respiratory syndrome Coronavirus Spike protein stability the spike protein Transmissibility Transmission Vaccine variant variant of SARS-CoV-2 variants variants of concern virus were used WHO [DOI] 10.1007/s11033-022-07545-4 PMC 바로가기 [Article Type] Article
Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection병원 내 SARS-CoV-2 델타 변이형 돌발성 감염에 대한 백신 접종 후 항체 평가Observational Study Published on 2022-07-252022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-S IgG Anti-spike anti-spike antibody antibody Asymptomatic B.1.617.2 BNT162b2 booster vaccination Breakthrough infection Care Casirivimab characterized collected coronavirus Course Delta variants diagnosed Diagnosis eight estimation geometric mean geometric mean titer GMT hospital Humoral immunity IgG Imdevimab Infection Inpatient LAMP Loop-mediated isothermal amplification lowest measurement Mild mild to moderate mild to moderate severity moderate monoclonal antibody mRNA vaccination nosocomial observational study outbreak public health quantified RBD protein remained respiratory retrospective risk RT-PCR SARS-CoV-2 SARS-CoV-2 delta SARS-COV-2 infection SARS-CoV-2 vaccination Sequencing serological serum sample serum samples Seven severe acute respiratory syndrome Coronavirus severity therapy Treatment uninfected vaccination variant virus viruses was done whole-genome sequencing [DOI] 10.1371/journal.pone.0272056 PMC 바로가기 [Article Type] Observational Study
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variantsDelta × Omicron 하이브리드 mRNA 백신의 추가 용량은 Omicron 및 기타 SARS-CoV-2 변이체에 대한 광범위 중화 항체를 생성했습니다.Article Published on 2022-07-072022-09-11 Journal: Journal of Biomedical Science [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antigenic approach booster dose CD8+ conserved COVID-19 cross-protective Cross-protectivity Delta Delta variants develop Efficacy elicited epitope feasible hybrid Hybrid vaccine Immune escape immunized Inclusion mice mRNA vaccine mRNA vaccine. mRNA-based vaccine Mutation naïve Neutralizing Neutralizing antibodies neutralizing antibody new SARS-CoV-2 Next generation vaccine omicron Omicron vaccine produced RBD Receptor binding domain SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants shown specific neutralizing antibodies T cell T cell response T cell responses tested Transmission Vaccine Vaccine design Vaccines variant variants variants of concern VOCs wild type wild-type [DOI] 10.1186/s12929-022-00830-1 PMC 바로가기 [Article Type] Article